| Year |
Citation |
Score |
| 2019 |
Pucilowska J, Egan J, Berinstein N, Moxon N, Aliabadi-Wahle S, Imatani J, Conlin A, Acheson A, Massimino K, Martel M, Campbell M, Wu Y, Sun Z, Redmond W, Shah M, et al. Abstract P2-09-12: Perilymphatic IRX-2 cytokine therapy to enhance tumor infiltrating lymphocytes (TILs) and PD-L1 expression preceding curative-intent therapy in early stage breast cancer (ESBC) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P2-09-12 |
0.351 |
|
| 2019 |
Berinstein N, Bence-Buckler I, Laneuville P, Stewart D, Smyth L, Kerr C, Klein G, Pennell N, Roos-Assar K. SPIReL: PHASE 2 STUDY DPX-SURVIVAC WITH INTERMITTENT LOW DOSE CYCLOPHOSPHAMIDE AND PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Hematological Oncology. 37: 569-569. DOI: 10.1002/Hon.16_2632 |
0.348 |
|
| 2018 |
Wolf GT, Moyer JS, Kaplan MJ, Newman JG, Egan JE, Berinstein NL, Whiteside TL. IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers. Oncotargets and Therapy. 11: 3731-3746. PMID 29988729 DOI: 10.2147/Ott.S165411 |
0.414 |
|
| 2018 |
Abdul-Wahid A, Cydzik M, Fischer NW, Prodeus A, Shively JE, Martel A, Alminawi S, Ghorab Z, Berinstein NL, Gariépy J. Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells. International Journal of Cancer. PMID 29756328 DOI: 10.1002/Ijc.31586 |
0.353 |
|
| 2018 |
Berinstein NL, McNamara M, Nguyen A, Egan J, Wolf GT. Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen. Oncoimmunology. 7: e1423173. PMID 29721379 DOI: 10.1080/2162402X.2017.1423173 |
0.452 |
|
| 2018 |
Berinstein NL, Pennell NM, Weerasinghe R, Buckstein R, Piliotis E, Imrie KR, Chodirker L, Cussen MA, Miles E, Reis MD, Ghorab Z, Cheung MC. Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with Y ibritumomab tiuxetan in a phase II study. Hematological Oncology. PMID 29709062 DOI: 10.1002/Hon.2513 |
0.353 |
|
| 2018 |
Smyth L, Buckstein R, Pennell N, Weerasinghe R, Cheung MC, Imrie K, Spaner D, Piliotis E, Chodirker L, Reis M, Ghorab Z, Zhang L, Boudreau V, Miliken A, Berinstein N. Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma. British Journal of Haematology. PMID 29380359 DOI: 10.1111/Bjh.15118 |
0.327 |
|
| 2018 |
Page DB, Pucilowska J, Berinstein NL, Egan JE. Tumor infiltrating lymphocyte recruitment in patients with early stage breast cancer after intramammary IRX-2 cytokine immunotherapy. Journal of Clinical Oncology. 36: 7-7. DOI: 10.1200/Jco.2018.36.5_Suppl.7 |
0.414 |
|
| 2017 |
Smyth L, Buckstein R, Nancy P, Weerasinghe R, Cheung M, Piliotis E, Imrie K, Spaner D, Reis MD, Chodirker L, Ghorab Z, ruth,nancy MV, Boudreau A, Berinstein N. Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α Blood. 130: 4069-4069. DOI: 10.1182/Blood.V130.Suppl_1.4069.4069 |
0.313 |
|
| 2017 |
Berinstein N, Smyth L, Pennell N, Weerasinghe R, Cheung M, Imrie K, Spaner D, Chodirker L, Piliotis E, Milliken V, Boudreau A, Zhang L, Reis M, Chesney A, Good D, et al. PROLONGED MOLECULAR AND CLINICAL REMISSIONS IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH HDT/ASCT AND COMBINATION IMMUNOTHERAPY WITH RITUXIMAB AND INTERFERON α Hematological Oncology. 35: 365-366. DOI: 10.1002/Hon.2439_120 |
0.313 |
|
| 2016 |
Davison K, Chen BE, Kukreti V, Couban S, Benger A, Berinstein N, Kaizer L, Desjardins P, Mangel J, Zhu L, Djurfeldt MS, Hay AE, Shepherd L, Crump M. Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the Phase III CCTG LY.12 Trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 27993811 DOI: 10.1093/Annonc/Mdw653 |
0.34 |
|
| 2016 |
Weir GM, Hrytsenko O, Quinton T, Berinstein NL, Stanford MM, Mansour M. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. Journal For Immunotherapy of Cancer. 4: 68. PMID 27777777 DOI: 10.1186/S40425-016-0169-2 |
0.363 |
|
| 2016 |
Berinstein NL, Van Der Jagt RHC, Cheung MC, Buckstein R, Karkada M, Quinton T, MacDonald L, Stanford M, Nigam R, Mansour M. A phase 2 clinical trial testing DPX-Survivac and metronomic low dose cyclophosphamide as immunotherapy for patients with recurrent diffuse large b-cell lymphoma. Journal of Clinical Oncology. 34: e14578-e14578. DOI: 10.1200/Jco.2016.34.15_Suppl.E14578 |
0.389 |
|
| 2016 |
Villella JA, Wilson MK, Berinstein NL, Karkada M, Quinton T, Butler MO, Lheureux S, Mandilaras V, Dhani NC, Weir G, MacDonald L, Nigam R, Stanford M, Mansour M, Oza AM. Determination of optimal dose and treatment schedule of the immunotherapeutic vaccine, DPX-Survivac, for combination immunotherapy treatment of ovarian, fallopian tube or peritoneal cancer (OC): A phase Ib study. Journal of Clinical Oncology. 34: e14577-e14577. DOI: 10.1200/Jco.2016.34.15_Suppl.E14577 |
0.319 |
|
| 2016 |
Berinstein NL, Pennell NM, Weerasinghe R, Cheung MC, Piliotis E, Imrie KR, Cussen M, Buckstein R, Ghorab Z, Miles E, Reis MD. Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan Blood. 128: 1794-1794. DOI: 10.1182/Blood.V128.22.1794.1794 |
0.405 |
|
| 2016 |
Weir GM, Hrytsenko O, Stanford M, Karkada M, Berinstein N, Mansour M. Abstract A137: Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and PD-1 blockade provides effective tumor control through a mechanism of epitope spreading Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A137 |
0.384 |
|
| 2016 |
Weir G, Hrytsenko O, Jagt Rvd, Cheung M, Buckstein R, Quinton T, MacDonald L, Nigam R, Mansour M, Berinstein NL, Stanford M. Abstract B113: Translational studies demonstrate that treatment with anti-PD-1 in unresponsive tumors can be improved by enhancing T cell activation in the tumor microenvironment with vaccine based immune therapy Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B113 |
0.351 |
|
| 2015 |
Da Silva DM, Woodham AW, Naylor PH, Egan JE, Berinstein NL, Kast WM. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. PMID 26653678 DOI: 10.1089/Jir.2015.0115 |
0.31 |
|
| 2015 |
Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, et al. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 4: e1026529. PMID 26405584 DOI: 10.1080/2162402X.2015.1026529 |
0.41 |
|
| 2015 |
Berinstein NL, Bhella S, Pennell NM, Cheung MC, Imrie KR, Spaner DE, Milliken V, Zhang L, Hewitt K, Boudreau A, Reis MD, Chesney A, Good D, Ghorab Z, Hicks LK, et al. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab. Annals of Hematology. 94: 813-23. PMID 25567231 DOI: 10.1007/S00277-014-2288-5 |
0.373 |
|
| 2015 |
Prica A, Pratzer A, Cheung M, Thompson K, Piliotis E, Berinstein NL, Imrie K, Pradhan R, Vyas A, Ghorab Z, Good D, Zhang L, Buckstein R. Rituximab Improves Overall Survival in Patients Treated with CODOX-M/IVAC for Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and BL (BCL-U): A Single Center Experience and Review of the Literature Journal of Cancer Therapy. 6: 1-11. DOI: 10.4236/Jct.2015.61001 |
0.368 |
|
| 2015 |
Villella JA, Wilson MK, Berinstein NL, Brown J, Lheureux S, Butler MO, Ramsahai J, Odunsi K, Karkada M, Nemunaitis JJ, Morse M, Pejovic T, Bentley J, Weir G, MacDonald L, et al. Safety, immunogenicity, and clinical activity of the immunotherapeutic vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian tube, or peritoneal cancer. Journal of Clinical Oncology. 33: 3072-3072. DOI: 10.1200/Jco.2015.33.15_Suppl.3072 |
0.406 |
|
| 2015 |
Hrytsenko O, Weir GM, Karkada M, Berinstein NL, Stanford MM, Mansour M. Abstract POSTER-THER-1415: Translational study of DPX-survivac peptide vaccine and metronomic cyclophosphamide using a novel HLA-A2/ survivin expressing ovarian tumor model to mimic phase I clinical data Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1415 |
0.373 |
|
| 2015 |
Weir G, Hrytsenko O, Stanford M, Karkada M, Berinstein N, Mansour M. Abstract 2508: Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and anti-PD1 monoclonal antibody provides effective control of tumors in multiple models Cancer Research. 75: 2508-2508. DOI: 10.1158/1538-7445.Am2015-2508 |
0.379 |
|
| 2014 |
Weir GM, Hrytsenko O, Stanford MM, Berinstein NL, Karkada M, Liwski RS, Mansour M. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. Oncoimmunology. 3: e953407. PMID 25960932 DOI: 10.4161/21624011.2014.953407 |
0.373 |
|
| 2014 |
Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1797-803. PMID 24799467 DOI: 10.1200/Jco.2012.43.9273 |
0.329 |
|
| 2014 |
Karkada M, Berinstein NL, Mansour M. Therapeutic vaccines and cancer: focus on DPX-0907. Biologics : Targets & Therapy. 8: 27-38. PMID 24596453 DOI: 10.2147/Btt.S55196 |
0.361 |
|
| 2014 |
Guirguis HR, Cheung MC, Piliotis E, Spaner D, Berinstein NL, Imrie K, Zhang L, Buckstein R. Survival of patients with transformed lymphoma in the rituximab era. Annals of Hematology. 93: 1007-14. PMID 24414374 DOI: 10.1007/S00277-013-1991-Y |
0.338 |
|
| 2014 |
Wilson M, Villella JA, Berinstein NL, Brown J, Lheureux S, Haley A, Odunsi K, Karkada M, Nemunaitis JJ, Morse M, Pejovic T, Bentley J, Weir G, MacDonald L, Sammatur L, et al. Phase I/Ib clinical and immunologic assessment of immunotherapeutic vaccine, DPX-Survivac in women with ovarian, Fallopian tube, or peritoneal cancer (OC). Journal of Clinical Oncology. 32: 5555-5555. DOI: 10.1200/Jco.2014.32.15_Suppl.5555 |
0.402 |
|
| 2014 |
Weir G, Hrytsenko O, Stanford M, Berinstein N, Liwski R, Karkada M, Mansour M. Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and anti-PD1 monoclonal antibody provides effective control of tumors in multiple models Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P130 |
0.377 |
|
| 2014 |
Weir G, Hrytsenko O, Stanford MM, Berinstein NL, Karkada M, Liwski RS, Mansour M. Abstract 5028: Metronomic cyclophosphamide enhances the immunogenicity and anti-tumor activity of a DepoVax based vaccine and may be further enhanced with inhibitors of CTLA-4 or PD-1 Cancer Research. 74: 5028-5028. DOI: 10.1158/1538-7445.Am2014-5028 |
0.384 |
|
| 2013 |
Berinstein NL, Oza AM, Odunsi K, Karkada M, Villella JA, Nemunaitis JJ, Morse M, Pejovic T, Bentley J, Nigam R, Weir G, MacDonald L, Stanford M, Burzykowski T, Mansour M. Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study. Journal of Clinical Oncology. 31: 3030-3030. DOI: 10.1200/Jco.2013.31.15_Suppl.3030 |
0.41 |
|
| 2013 |
Karkada M, Ogura M, Tovar V, Mitsuhashi M, Berinstein N, Mansour M. Immunological and polyfunctional T cell profiling following therapy with DPX-Survivac as a predictive tool of vaccine efficacy Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P106 |
0.385 |
|
| 2013 |
Pratzer A, Cheung MC, Thompson K, Piliotis E, Berinstein NL, Imrie KR, Pradhan R, Vyas A, Good D, Zhang L, Buckstein R. Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature Blood. 122: 5093-5093. DOI: 10.1182/Blood.V122.21.5093.5093 |
0.367 |
|
| 2013 |
Kuruvilla J, Kouroukis CT, Benger A, Cheung MC, Berinstein NL, Couban S, Seftel MD, Howson-Jan K, Keating A, Federico M, Macdonald DA, Olney HJ, Rubinger M, Voralia M, Turner AR, et al. A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12 Blood. 122: 155-155. DOI: 10.1182/Blood.V122.21.155.155 |
0.322 |
|
| 2013 |
Weir GM, Stanford MM, Berinstein NL, Karkada M, Liwski RS, Mansour M. Abstract 2836: Metronomic cyclophosphamide enhances antitumor immune response induced by a DepoVaxTM-based peptide vaccine. Cancer Research. 73: 2836-2836. DOI: 10.1158/1538-7445.Am2013-2836 |
0.381 |
|
| 2013 |
Weir GM, Berinstein NL, Hrytsenko O, Karkada M, Stanford MM, Mansour M. Abstract A84: Metronomic cyclophosphamide, when combined with vaccination, increases the immunogenicity of the vaccine and modulates the tumor microenvironment to provide better anti-tumor activity Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-A84 |
0.366 |
|
| 2012 |
Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. Journal of Translational Medicine. 10: 156. PMID 22862954 DOI: 10.1186/1479-5876-10-156 |
0.318 |
|
| 2012 |
Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. British Journal of Haematology. 159: 39-49. PMID 22849793 DOI: 10.1111/J.1365-2141.2012.09247.X |
0.344 |
|
| 2012 |
Whiteside TL, Butterfield LH, Naylor PH, Egan JE, Hadden JW, Baltzer L, Wolf GT, Berinstein NL. A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. Cancer Immunology, Immunotherapy : Cii. 61: 783-8. PMID 22109700 DOI: 10.1007/S00262-011-1136-X |
0.352 |
|
| 2012 |
Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, Whiteside TL, Goldstein LC, El-Naggar A, Badoual C, Fridman WH, White JM, Hadden JW. Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunology, Immunotherapy : Cii. 61: 771-82. PMID 22057678 DOI: 10.1007/S00262-011-1134-Z |
0.333 |
|
| 2012 |
Berinstein NL, Karkada M, Nigam R, Morse M, Nemunaitis JJ, Chatta GS, Kaufman H, Odunsi K, Weir G, MacDonald L, Stanford M, Mansour M. Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients. Journal of Clinical Oncology. 30: 2588-2588. DOI: 10.1200/Jco.2012.30.15_Suppl.2588 |
0.368 |
|
| 2012 |
Berinstein NL, Pennell NM, Cussen M, Imrie KR, Piliotis E, Buckstein R, Ghorab Z, Miles EA, Chesney AE, Cheung M. Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab Blood. 120: 3681-3681. DOI: 10.1182/Blood.V120.21.3681.3681 |
0.415 |
|
| 2012 |
Weir G, Stanford M, Karkada M, Berinstein N, Mansour M. Abstract 4405: Immune modulation and Treg suppression with metronomic cyclophosphamide enhances the anti-tumor effect of a therapeutic peptide vaccine in a murine model Cancer Research. 72: 4405-4405. DOI: 10.1158/1538-7445.Am2012-4405 |
0.362 |
|
| 2011 |
Berinstein NL, Morse M, Kaufman H, Nemunaitis JJ, Odunsi K, Chatta GS, Weir G, MacDonald L, Stanford M, Karkada M, Nigam R, Mansour M. A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13050. PMID 28019867 DOI: 10.1200/Jco.2011.29.15_Suppl.E13050 |
0.32 |
|
| 2011 |
Naylor PH, Egan JE, Berinstein NL. Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen. Cancers. 3: 3991-4009. PMID 24213121 DOI: 10.3390/Cancers3043991 |
0.366 |
|
| 2011 |
Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, et al. Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine. 9: 214. PMID 22168571 DOI: 10.1186/1479-5876-9-214 |
0.301 |
|
| 2011 |
Mozessohn L, Cheung M, Crump M, Buckstein R, Berinstein NL, Imrie KR, Kuruvilla J, Piliotis E, Kukreti V. Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis Blood. 118: 4981-4981. DOI: 10.1182/Blood.V118.21.4981.4981 |
0.336 |
|
| 2011 |
Pennell NM, Cheung M, Hicks LK, Piliotis E, Imrie KR, Buckstein R, Davidson C, Cussen M, Ghorab Z, Chesney A, Berinstein NL. First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan (90Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma Blood. 118: 2701-2701. DOI: 10.1182/Blood.V118.21.2701.2701 |
0.421 |
|
| 2010 |
Vogel TU, Visan L, Ljutic B, Gajewska B, Caterini J, Salha D, Wen T, He L, Parrington M, Cao SX, McNeil B, Sandhu D, Scollard N, Zhang L, Bradley B, ... ... Berinstein NL, et al. Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 743-58. PMID 20842062 DOI: 10.1097/Cji.0B013E3181Eccc87 |
0.383 |
|
| 2010 |
Mahrous M, Buckstein R, Piliotis E, Cheung MC, Berinstein NL. Effect of a rituximab-based regimen on the incidence of CNS relapse in patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology. 28: 8098-8098. DOI: 10.1200/Jco.2010.28.15_Suppl.8098 |
0.363 |
|
| 2010 |
Bhella S, Berinstein NL, Pennell N, Cheung M, Imrie KR, Miliken V, Reis MD, Chesney A, Good D, Hicks L, Piliotis E, Crump M, Buckstein R. The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions Blood. 116: 1357-1357. DOI: 10.1182/Blood.V116.21.1357.1357 |
0.377 |
|
| 2009 |
Berinstein NL. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. Annals of the New York Academy of Sciences. 1174: 107-17. PMID 19769743 DOI: 10.1111/J.1749-6632.2009.04935.X |
0.383 |
|
| 2009 |
Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, Zhang L, Imrie K, Spaner D, Cheung MC, Boudreau A, Reis M, Crump M, Berinstein NL. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplantation. 43: 701-8. PMID 19029963 DOI: 10.1038/Bmt.2008.382 |
0.332 |
|
| 2009 |
Mahrous Mohamed M, Buckstein R, Piliotis E, Cheung MC, Berinstein N. Rituximab Based Regimen May Decrease the Incidence of CNS Relapse in Patients with Diffuse Large B-Cell Lymphoma. Blood. 114: 4770-4770. DOI: 10.1182/Blood.V114.22.4770.4770 |
0.371 |
|
| 2008 |
Pennell N, Cheung M, Hicks LK, Buckstein R, Imrie KR, Piliotis E, Spaner D, Ghorab Z, Reis MD, Milliken V, Boudreau A, Berinstein N. Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies Blood. 112: 4351-4351. DOI: 10.1182/Blood.V112.11.4351.4351 |
0.378 |
|
| 2007 |
Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine. 25: B72-88. PMID 17916464 DOI: 10.1016/J.Vaccine.2007.06.043 |
0.378 |
|
| 2006 |
Berinstein NL. Principles of maintenance therapy. Leukemia Research. 30: S3-10. PMID 16750676 DOI: 10.1016/S0145-2126(06)80002-0 |
0.321 |
|
| 2006 |
Pennell N, Woods A, Reis M, Buckstein R, Spaner D, Imrie K, Hewitt K, Boudreau A, Seth A, Berinstein NL. Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction. The Journal of Molecular Diagnostics : Jmd. 8: 40-50. PMID 16436633 DOI: 10.2353/Jmoldx.2006.050050 |
0.33 |
|
| 2006 |
Hicks L, Buckstein R, Mangel J, Piliotis E, Imrie K, Cheung MC, Spaner DE, Reis MD, Ghorab Z, Milliken V, Pennell N, Berinstein N. Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma. Blood. 108: 3067-3067. DOI: 10.1182/Blood.V108.11.3067.3067 |
0.383 |
|
| 2006 |
Hicks L, Connors JM, Mangel J, Buckstein R, Crump M, Leitch H, Imrie K, Nagy T, Boudreau A, Pennell N, Spaner D, Berinstein N. Autologous Stem-Cell Transplant with a Rituximab Purge and Maintenance vs. Standard Chemotherapy for Mantle Cell Lymphoma: Extended Follow-Up of a Matched Pair Analysis. Blood. 108: 3051-3051. DOI: 10.1182/Blood.V108.11.3051.3051 |
0.368 |
|
| 2005 |
Tomlin JL, Guinn BA, Penn LZ, Berinstein NL. Bcl-2 and c-Myc co-operate in the Epstein-Barr virus-immortalized human B-cell line GM607 but do not confer tumorigenicity. Leukemia & Lymphoma. 46: 581-92. PMID 16019487 DOI: 10.1080/10428190400019867 |
0.376 |
|
| 2005 |
Buckstein R, Pennell N, Berinstein NL. What is remission in follicular lymphoma and what is its relevance? Best Practice & Research. Clinical Haematology. 18: 27-56. PMID 15694183 DOI: 10.1016/J.Beha.2004.08.019 |
0.344 |
|
| 2004 |
Berinstein NL, Mangel J. Integrating Monoclonal Antibodies into the Management of Mantle Cell Lymphoma. Seminars in Oncology. 31: 2-6. PMID 28140105 DOI: 10.1053/J.Seminoncol.2003.12.002 |
0.39 |
|
| 2004 |
Woods AC, Buckstein R, Mangel J, Imrie K, Spaner D, Crump M, Pennell N, Boudreau A, Reis M, Berinstein N. High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions. Blood. 104: 914-914. DOI: 10.1182/Blood.V104.11.914.914 |
0.308 |
|
| 2004 |
Hicks L, Buckstein R, Piliotis E, Mangel J, Imrie K, Spaner DE, Reis MD, Foden C, Milliken V, Boudreau A, Richardson P, Pennell N, Berinstein N. Rituximab + ESHAP as Salvage Chemotherapy for Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma: A Phase II Trial. Blood. 104: 5230-5230. DOI: 10.1182/Blood.V104.11.5230.5230 |
0.379 |
|
| 2004 |
Pennell N, Woods A, Buckstein R, Imrie K, Spaner D, Reis M, Berinstein N. A Simplified Real-Time PCR Method for the Quantification of Minimal Residual Disease in Follicular Lymphoma. Blood. 104: 5203-5203. DOI: 10.1182/Blood.V104.11.5203.5203 |
0.35 |
|
| 2001 |
Gitelson E, Ghose A, Buckstein R, Imrie K, Lim MS, Reis M, Spaner D, Tartaglia J, Berinstein NL. ALVAC-mediated gene transfer is efficient in lymphoid malignancies of T-and early B-cell origin, but not in tumors arising from mature B-cells. Cancer Immunology, Immunotherapy : Cii. 50: 345-55. PMID 11676394 DOI: 10.1007/S002620100209 |
0.337 |
|
| 2001 |
Buckstein RJ, Rimrie K, Pennell N, Spaner D, Hewitt K, Berinstein NL. Prolonged molecular and clinical remission after treatment of a patient with follicular lymphoma with Rituximab Leukemia and Lymphoma. 41: 451-455. PMID 11378562 DOI: 10.3109/10428190109058004 |
0.347 |
|
| 2001 |
MacKenzie RG, Franssen E, Wong R, Sawka C, Berinstein N, Cowan DH, Senn J, Poldre P. Risk-adapted therapy for clinical stage I-II Hodgkin's disease: 7-years results of radiotherapy alone for low-risk disease, and ABVD and radiotherapy for high-risk disease. Clinical Oncology (Royal College of Radiologists (Great Britain)). 12: 278-88. PMID 11315710 DOI: 10.1053/Clon.2000.9174 |
0.302 |
|
| 2000 |
Fong IC, Zarrin AA, Wu GE, Berinstein NL. Functional analysis of the human RAG 2 promoter. Molecular Immunology. 37: 391-402. PMID 11074256 DOI: 10.1016/S0161-5890(00)00056-0 |
0.677 |
|
| 2000 |
Ghose A, Iakhnina E, Spaner D, Tartaglia J, Berinstein NL. Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector. Human Gene Therapy. 11: 1289-301. PMID 10890739 DOI: 10.1089/10430340050032393 |
0.347 |
|
| 2000 |
Verkoczy LK, Guinn Ba, Berinstein NL. Characterization of the human B cell RAG-associated gene, hBRAG, as a B cell receptor signal-enhancing glycoprotein dimer that associates with phosphorylated proteins in resting B cells. The Journal of Biological Chemistry. 275: 20967-79. PMID 10749872 DOI: 10.1074/Jbc.M001866200 |
0.666 |
|
| 2000 |
Haq R, Sawka CA, Franssen E, Berinstein NL. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. Leukemia & Lymphoma. 35: 527-36. PMID 10609790 DOI: 10.1080/10428199909169617 |
0.328 |
|
| 1999 |
Campbell C, Sawka C, Franssen E, Berinstein NL. Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support. Leukemia & Lymphoma. 35: 119-27. PMID 10512169 DOI: 10.3109/10428199909145711 |
0.319 |
|
| 1999 |
Zarrin AA, Malkin L, Fong I, Luk KD, Ghose A, Berinstein NL. Comparison of CMV, RSV, SV40 viral and Vlambda1 cellular promoters in B and T lymphoid and non-lymphoid cell lines. Biochimica Et Biophysica Acta. 1446: 135-9. PMID 10395926 DOI: 10.1016/S0167-4781(99)00067-6 |
0.678 |
|
| 1998 |
Piovesan B, Pennell N, Berinstein NL. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity. Oncogene. 17: 2339-50. PMID 9811465 DOI: 10.1038/Sj.Onc.1202147 |
0.331 |
|
| 1998 |
Verkoczy LK, Marsden PA, Berinstein NL. hBRAG, a novel B cell lineage cDNA encoding a type II transmembrane glycoprotein potentially involved in the regulation of recombination activating gene 1 (RAG1). European Journal of Immunology. 28: 2839-53. PMID 9754571 DOI: 10.1002/(Sici)1521-4141(199809)28:09<2839::Aid-Immu2839>3.0.Co;2-6 |
0.68 |
|
| 1998 |
Verkoczy LK, Berinstein NL. Isolation of genes negatively or positively co-expressed with human recombination activating gene 1 (RAG1) by differential display PCR (DD RT-PCR). Nucleic Acids Research. 26: 4497-507. PMID 9742255 DOI: 10.1093/Nar/26.19.4497 |
0.644 |
|
| 1997 |
Zarrin AA, Fong I, Malkin L, Marsden PA, Berinstein NL. Cloning and characterization of the human recombination activating gene 1 (RAG1) and RAG2 promoter regions. Journal of Immunology (Baltimore, Md. : 1950). 159: 4382-94. PMID 9379036 |
0.669 |
|
| 1997 |
Tang SC, Hewitt K, Reis MD, Berinstein NL. Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leukemia & Lymphoma. 24: 93-101. PMID 9049965 DOI: 10.3109/10428199609045717 |
0.342 |
|
| 1995 |
Stiernholm NB, Verkoczy LK, Berinstein NL. Rearrangement and expression of the human psi C lambda 6 gene segment results in a surface Ig receptor with a truncated light chain constant region. Journal of Immunology (Baltimore, Md. : 1950). 154: 4583-91. PMID 7722311 |
0.604 |
|
| 1995 |
Verkoczy LK, Stiernhdm BJ, Berinstein NL. Up-regulation of recombination activating gene expression by signal transduction through the surface Ig receptor. Journal of Immunology (Baltimore, Md. : 1950). 154: 5136-43. PMID 7537300 |
0.652 |
|
| 1994 |
Stiernholm NB, Berinstein NL. Immunoglobulin somatic variation; studies of receptor editing in a human B cell lymphoma. Leukemia & Lymphoma. 12: 333-41. PMID 8180597 DOI: 10.3109/10428199409073774 |
0.436 |
|
| 1994 |
Haw R, Sawka CA, Franssen E, Berinstein NL. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. Journal of Clinical Oncology. 12: 1074-1084. PMID 8164032 DOI: 10.1200/Jco.1994.12.5.1074 |
0.349 |
|
| 1994 |
Farrugia M, Duan L, Reis M, Ngan B, Berinstein N. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes Blood. 83: 191-198. DOI: 10.1182/Blood.V83.1.191.Bloodjournal831191 |
0.387 |
|
| 1993 |
Stiernholm NB, Berinstein NL. Up-regulated recombination-activating gene expression in sIg- variants of a human mature B cell line undergoing secondary Ig lambda rearrangements in cell culture. European Journal of Immunology. 23: 1501-7. PMID 8325326 DOI: 10.1002/Eji.1830230716 |
0.438 |
|
| 1993 |
Berinstein NL, Reis MD, Ngan BY, Sawka CA, Jamal HH, Kuzniar B. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 1344-52. PMID 8315432 DOI: 10.1200/Jco.1993.11.7.1344 |
0.315 |
|
| 1992 |
Stiernholm N, Kuzniar B, Berinstein N. Absence of immunoglobulin variable region hypermutation in a large cell lymphoma after in vivo and in vitro propagation Blood. 80: 738-743. DOI: 10.1182/Blood.V80.3.738.Bloodjournal803738 |
0.423 |
|
| 1989 |
Berinstein N, Levy S, Levy R. Activation of an excluded immunoglobulin allele in a human B lymphoma cell line. Science (New York, N.Y.). 244: 337-9. PMID 2496466 DOI: 10.1126/Science.2496466 |
0.394 |
|
| Show low-probability matches. |